Roche receives CE mark for Contivue, its Port Delivery Platform containing Susvimo, for neovascular age-related macular degeneration (nAMD)
(RO) Basel, 04 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received the EU CE mark for its Port Delivery Platform containing Susvimo, which will now be known as ...
When is the EMA decision expected for Susvimo, and what are the potential pricing and reimbursement implications in the EU market?
What competitive advantages does Contivue offer over existing nAMD delivery platforms from companies like Novartis and Alcon, and how might this influence market share?
How will the CE marking of Contivue with Susvimo affect Roche's upcoming quarterly earnings and revenue forecasts?
Symbol:
RO
4 days ago